A director at Amryt Pharma bought 250,000 shares at 1.880USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT ANNOUNCES POSITIVE TOP LINE RESULTS FROM PIVOTAL PHASE 3 “EASE” TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA - Primary endpoint met with statistical significance (p-value = 0.013) - FILSUVEZ® demonstrated a good safety profile - EASE is the first Phase 3 trial to demonstrate a statistically significant increase in speed of wound healing in Epidermolysis Bullosa - Rolling US regulatory submissions already underway with FDA with priority review request planned - EU regulatory submiss...
AMRYT PHARMA NOTIFICATION OF CANCELLATION OF ADMISSION TO EURONEXT GROWTH AMRYT PHARMA PLC (“Amryt” or the “Company”) NOTIFICATION OF CANCELLATION OF ADMISSION TO EURONEXT GROWTH DUBLIN, Ireland, and Boston MA, August 11, 2020, Amryt, (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that it has given Euronext Dublin (“Euronext”) notice of its intention to cancel the admission of t...
AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020 AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020 New revenue guidance of $170M - $175M in 2020 Conference call and webcast today 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, August 6, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces unaudited financial...
AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE Monday, August 3, 2020 at 1000 ET / 1500 BST DUBLIN, Ireland, and Boston MA, July 29 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces it will host a Key Opinion Lea...
AMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020 AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020 DUBLIN, Ireland, and Boston MA, July 20 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that the Company will issue unaudited financial results for the second quarter ended June 30, 2020 on August 6, 2020 at 1200 (BST) / 0700 (ET). ...
AMRYT LISTED ON NASDAQ AND CEO TO RING NASDAQ CLOSING BELL THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT LISTED ON NASDAQ AND CEO TO RING NASDAQ CLOSING BELL DUBLIN, Ireland, and Boston MA, July 8 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from seri...
AMRYT PHARMA PLC: Posting of Annual Report and Notice of Agm THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION AMRYT PHARMA PLC (“Amryt” or the “Company”) POSTING OF ANNUAL REPORT AND NOTICE OF AGM DUBLIN, Ireland, and Boston MA, June 30, 2020, Amryt Pharma (AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces that copies of the 2019 Annual Report have...
Amryt publicly files registration statement for impending US listing on Nasdaq THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE AMRYT PHARMA PLC (“Amryt” or the “Company”) Amryt publicly files registration statement for impending US listing on Nasdaq DUBLIN, Ireland, and Boston MA, June 23, 2020, Amryt Pharma (AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel ther...
AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”) June 3, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”) Amryt, a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of a distribution agreement with Swixx BioPharma A...
Amryt Pharma Plc - Full Year 2019 RESULTS May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) FY 2019 RESULTS Transformational year of performance and growth for AmrytAegerion integration completed successfully and ahead of scheduleBusiness performing ahead of expectationsStrong year end cash balances of $65.2MUnaudited combined revenues of $154.1M in 2019, an increase of 13.1% on 2018 unaudited combined revenues of $136.3M1The Company has also today separately issued Q1 results for 2020 Amryt, a global, commercial-stage biopharmaceutical com...
Amryt Pharma Plc - Q1 2020 RESULTS May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) Q1 2020 RESULTS $44.6M unaudited Q1 revenues representing a 30% increase on unaudited combined revenues of $34.3M in Q1 2019110% quarter on quarter unaudited revenue growth in Q1 2020 versus Q4 2019 ($40.5M)$4.6M EBITDA2 delivered in Q1. Including non-cash items and share based compensation expenses, this results in an operating loss before finance expense for Q1 of $17.0MCash generated from Operating Activities of $6.2M during Q1 2020Aegerion integration successfull...
Filsuvez® Confirmed as Global Brand Name for Ap101 7 May 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) FILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101 Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that the global brand name for its lead development product AP101 will be FILSUVEZ®. Amryt announced on 23 April 2020 that the Company has completed recruitment into its Global Phase 3 clin...
Notice of Results 07 May 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) Notice of Results Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that its results for the year ended 31 December 2019 will be released on 11 May 2020. Amryt will also issue Q1 2020 results on 11 May 2020. Management will host a conference call for analysts and investors at 14.30 BST on 11 May 2020. Dial in details f...
Amryt Pharma plc: Lojuxta to be reimbursed in France 17 October 2018AIM: AMYTESM: AYP Amryt Pharma plc(“Amryt” or the “Company”) Lojuxta to be reimbursed in France Amryt’s lead commercial product now available in all five of the EU’s largest markets Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help improve the lives of patients where there is a high unmet medical need, is pleased to announce that it has reached agreement with France’s CEPS (Comité économique des produits de santé), to reimburse Lojuxta® (lomitapide) for...
Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites 10 September 2018AIM: AMYT ESM: AYP Amryt Pharma plc(“Amryt” or the “Company”) Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites Amryt, a biopharmaceutical company focused on rare and orphan diseases, today announces that the US Food and Drug Administration (“FDA”) has granted Investigational New Drug (“IND”) clearance for AP101. This enables the Company to begin opening US clinical trial sites as part of its ongoing global EASE Phase III ...
Amryt Pharma plc: NHS England approves funding for Lojuxta 9 July 2018AIM: AMYT Amryt Pharma plc(“Amryt” or the “Company”) NHS England approves funding for Lojuxta Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that Lojuxta® (lomitapide) has been approved for funding as an NHS treatment for adult patients with Homozygous Familial Hypercholesterolaemia (“HoFH”) in England. The decision means that, from this year, patients with this ultra-rare, life-threatening genetic condition being treated on the NHS in England can be prescribed a ‘first...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.